




Gopinath S et al. Role of disease-associated tolerance in infectious superspreaders. PNAS 2014;111:15780


- 1997 Woodhouse 20% of infected hosts (superspreaders) are responsible for 80% of infections
- Demonstrated in cattle herds infected with E. coli 0157 H7
- Gopinath et al. used a mouse model of Salmonella to dissect the reasons for superspreaders
- Superspreaders have unique tolerance mechanisms that enable sustained pathogen transmission








WHO Research Question 1

Does a **restriction of use of antibiotic agent(s) in food animals** compared to not having that restriction reduce the presence of antibiotic resistant genetic elements and/or **antibiotic resistant bacteria in food animal** populations of any age in any setting?











Characteristics human studie			
Study Characteristic		No. studies (N=21)	
Intervention	Externally imposed restrictions	9	
	Organic interventions	2	
	Self-reported antibiotic-free	5	
	Voluntary reduction	5	
Bacteria studied	Campylobacter spp.	2	
	Enterococcus spp.	8	
	Enterobacteriaceae: <i>E. coli</i>	3	
	Enterobacteriaceae: Salmonella spp.	1	
	Staphylococcus spp.	8	





Conclusions human studies

Smaller number of human studies found (N=21)

Of these, 13 were pooled, showing a 24% reduction of antibiotic resistance in humans with interventions reducing antibiotic use in food animals


Mechanisms indirect

Effect stronger in farm workers

Findings held:


- Across strong versus weak interventions
- Regardless of whether interventions were well-described
- When meeting abstracts were removed
- When ecological studies were removed


However, quality of these studies was not great












WHO	Priority Pathogens List	for R & D of New Antibiotics (Feb,2017)
Priority 1:	Critical	A. baumanii, CP resistant P. aeruginosa, CP resistant Enterobacteriaceae, CP; ESBL (±)
Priority 2:	High	<i>E. faecalis</i> , VR MRSA, VR & Intermediate <i>H. pylori</i> , clarithromycin R <u>Campylobacter spp FQ res</u> Salmonella FQ res (±) <i>N. gonorrhea</i> , ceph res, FQ res
Priority 3:	Medium	S. pneumoniae Pen non-sus H. influenzae, amp res Shigella spp, FQ res (±)
	other dedicated programs	," ``


 \$264 million, 2016 Anticipated outcomes: Reduction Rate <i>C. difficile infection</i> 	
C. difficile infection	
	58%
Healthcare CRE	60%
HC MDR Pseudomonas	35%
Bloodstream MRSA	50%
MDR Salmonella	25%
Invasive pneumococcal disease	25%
MDR tuberculosis	15%
MDR gonorrhea	2%


Managing Antimicrobial Resistance: Human

- surveillance
- limit transmission (infection control)
 - acute care
 - long term care
 - community (±)
- decrease antimicrobial use (stewardship)
 - acute care
 - long term care
 - community
- innovation




























Drs. Nicole and Gyles – its OK – some people say there is no change in our climate



CAHS FORUM ON INDIGENOUS HEALTH SEPTEMBER 16, 2016